Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk
Executive Summary
After otherwise successful Phase II NASH trial showed Ocaliva can increase a patient's LDL cholesterol levels, Intercept hopes a study in NASH patients who use atorvastatin will show this effect is manageable.
You may also be interested in...
Enanta Stumbles In Trying To Show Better FXR Agonist Profile In NASH
Enanta hoped its Phase II study would indicate a better efficacy and/or tolerability profile for EDP-305 compared to other FXR agonists for NASH, including Intercept’s OCA. Despite the inconclusive data, it plans a longer Phase IIb study.
Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III
Primary endpoint miss for Phase III selonsertib in cirrhotic NASH patients follows disappointing data at both 2018 major liver conferences. STELLAR-3 in NASH patients with bridging fibrosis looms large for Gilead’s hopes.
Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.